Robert Browne
Finanzdirektor/CFO bei Viron Therapeutics, Inc.
Aktive Positionen von Robert Browne
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Finanzdirektor/CFO | - | - |
Karriereverlauf von Robert Browne
Ehemalige bekannte Positionen von Robert Browne
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TELESTA THERAPEUTICS INC | Finanzdirektor/CFO | - | - |
FENNEC PHARMACEUTICALS INC. | Finanzdirektor/CFO | - | - |
The Canadian Institute of Chartered Accountants
The Canadian Institute of Chartered Accountants Miscellaneous Commercial ServicesCommercial Services Canadian Institute of Chartered Accountants engages in the provision of accounting, auditing, tax, advisory, and professional services. The institute is headquartered in Toronto, Canada. | Corporate Officer/Principal | - | - |
Statistik
International
Kanada | 4 |
Vereinigte Staaten | 2 |
Operativ
Director of Finance/CFO | 3 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 4 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
FENNEC PHARMACEUTICALS INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
The Canadian Institute of Chartered Accountants
The Canadian Institute of Chartered Accountants Miscellaneous Commercial ServicesCommercial Services Canadian Institute of Chartered Accountants engages in the provision of accounting, auditing, tax, advisory, and professional services. The institute is headquartered in Toronto, Canada. | Commercial Services |
Telesta Therapeutics, Inc.
Telesta Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Telesta Therapeutics, Inc. is a biotechnology company, which focuses on the licensing/acquisition and development of transformational therapeutics for the treatment of serious human diseases, such as cancer, immune diseases, and targeted rare diseases. The company was founded by Graeme McRae in 1979 and is headquartered in Pointe-Claire, Canada. | Health Technology |
- Börse
- Insiders
- Robert Browne
- Erfahrung